Collaborative industry efforts have shed light on ways industry standards can help pharma companies better understand the risks nitrosamines pose to the supply chain.
IQ Consortium working groups have engaged in ongoing efforts to evaluate risk models and guidance documents to help increase pharma industry knowledge about these impurities.
Pharmaceutical Technology eBook: Regulatory Sourcebook, March 2021 Pages: 28–35
Citation
When referring to this article, please cite it as T. Curran and J.P. Bercu, "Managing the Risk of Nitrosamine Impurities," Pharmaceutical Technology Regulatory Sourcebook eBook (March 2021).
